Melanoma Clinical Trial
MElanoma Research Lymph Node Prediction Implementation National_001
Summary
MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
Eligibility Criteria
Inclusion Criteria:
Newly diagnosed patients with invasive malignant melanoma of the skin (AJCC 8th edition staging guidelines) elected to undergo sentinel lymph node biopsy per the treating physician's recommendation.
Male or female, age ≥18 years.
Exclusion Criteria:
Full primary melanoma pathology report unavailable.
Documented clinically apparent nodal metastases at diagnosis.
Distant metastatic disease (M1a,b,c,d) clinically present at primary diagnosis
Any prior or concurrent primary invasive melanoma mapping to the same draining lymph node basin(s).
Documented history of another (prior or concurrent) primary invasive melanoma of T1b or greater at any site within the last 5 years.
Previous surgery in or radiation therapy to the draining lymph node basin(s) of the current primary melanoma.
Ocular, vulvar, perianal or mucosal melanomas or melanocytic tumors of uncertain malignant potential (MELTUMP) or atypical Spitz tumors.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 9 Locations for this study
Atlanta Georgia, 30322, United States More Info
Contact
Louisville Kentucky, 40292, United States More Info
Contact
Ann Arbor Michigan, 48109, United States More Info
Contact
New York New York, 10065, United States More Info
Contact
Durham North Carolina, 27705, United States More Info
Contact
Salt Lake City Utah, 84112, United States More Info
Contact
How clear is this clinincal trial information?